LoadingLoadingLoadingThe quick read
Latest quote·Oct 13
Net selling: insiders sold $118.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $2K to $30K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $118.2M and bought $0 of SYK stock on the open market in the 90 days to Oct 15, 2026, according to SEC Form 4 filings. The largest was Stryker, Ronda E (Director), who sold $117.8M. The latest filing was on Aug 26, 2026.
Rep. Thomas H. Kean Jr sold $1K to $15K on Jul 22, 2026, disclosed 27 days later. Rep. Thomas H. Kean Jr sold $1K to $15K on Jun 2, 2026, disclosed 43 days later. In total, 1 member disclosed 2 SYK trades with trade dates in the last 180 days, filed a median 35 days after trading.
This summary uses filings available on Oct 15, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Sells/Trims (3)
Qube Research
$190.0M
sold
AQR
$167.6M
trimmed
Two Sigma
$150.1M
trimmed
Buys (1)
Brainerd Mary K
$27K
bought
Sells (2)
Crotty Dylan Bram
$145K
sold
Stryker Ronda E
$117.8M
sold
No tracked top-trader positions in SYK right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Jul 30, 2026
Financial period
Q2
Adjusted EPS
$3.49 expected
Revenue
No reported revenue on record
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | $3.69 / $3.49Yahoo Finance | +5.79% beat | Unavailable | Unavailable |
| Mar 31, 2026 | Apr 30, 2026 | $2.60 / $2.98Yahoo Finance | -12.86% miss | Unavailable | Unavailable |
| Dec 31, 2025 | Jan 29, 2026 | $4.47 / $4.40Yahoo Finance | +1.70% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 30, 2025 | $3.19 / $3.13Yahoo Finance | +1.87% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 31, 2025 | $3.13 / $3.07Alpha Vantage | +1.95% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 1, 2025 | $2.84 / $2.73Alpha Vantage | +4.03% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Jan 28, 2025 | $4.01 / $3.87Alpha Vantage | +3.62% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 29, 2024 | $2.87 / $2.77Alpha Vantage | +3.61% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 15, 2026
EPS expected
$3.44 to $3.80
Revenue expected
25 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $6.06B | $7.17B | $6.02B | $6.59B |
| Cost of what it sold | $2.21B | $2.49B | $2.21B | $2.09B |
| Gross profit | $3.85B | $4.68B | $3.81B | $4.50B |
| What it spent | ||||
| Research and development | $410.0M | $401.0M | $413.0M | $434.0M |
| Sales and admin | $2.04B | $2.13B | $2.28B | $2.23B |
| Other operating costs | $262.0M | $180.0M | $180.0M | $176.0M |
| Total operating expenses | $2.72B | $2.72B | $2.87B | $2.84B |
| What was left | ||||
| Operating profit | $1.14B | $1.96B | $936.0M | $1.66B |
| Interest on debt | $157.0M | $381.0M | $148.0M | $141.0M |
| Profit before tax | $1.03B | $1.71B | $850.0M | $1.56B |
| Tax | $170.0M | $856.0M | $105.0M | $288.0M |
| Net profit | $859.0M | $849.0M | $745.0M | $1.28B |
| EBITDA | $1.36B | $2.03B | $1.30B | $2.00B |
This stock's price action is mixed.
Trend
Mixed
55 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Stryker plans $400 million investment in CMR Surgical
NeutralOct 12Stryker Announces $400 Million Investment in CMR Surgical With Option for Full Acquisition
BullishOct 12Intuitive Surgical stock trades at EUR 380.75 with P/ E 48.4
NeutralOct 12Stryker Corp. stock underperforms Monday when compared to competitors despite daily gains
NeutralOct 12Stryker enters soft tissue robotics with $400M investment in CMR Surgical
Leans bullishOct 12Stryker enters soft tissue robotics with $400M investment in CMR Surgical
BullishOct 12Stryker invests $400m into CMR Surgical; secures future buyout option
BullishOct 12Stryker to Invest $400M in CMR Surgical, Gains U.S. Sales Rights and Acquisition Option
BullishOct 12